Gossamer Bio, Inc. (GOSS): Depreciation & Amortization
$24.0K
Year ended 2025-12-31
-76.4%
3-year compound annual growth
-55.7%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.0K | -97.1% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $833.0K | -48.2% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $1.61M | -12.3% | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | $1.83M | +5.3% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $1.74M | +23.5% | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | $1.41M | +53.7% | 2023-03-17, From 2020-01-01 |
| 2019-12-31 | $917.0K | +208.8% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $297.0K | n/a | 2021-02-26, From 2018-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $24.0K | -97.1% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $621.0K | +16.3% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.28M | +55.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $1.60M | +14.3% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $4.32M | +14.2% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $548.0K | -23.7% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.15M | -15.4% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $1.54M | -6.3% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $318.0K | +3.6% |
Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗